Physician profile
John P Papp
NPI 1417932872
$9,607.94
in general payments reported to CMS, 2019-2025
37 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $610 · 2021: $541 · 2022: $1,447 · 2023: $2,318 · 2024: $1,790 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472 · Education: $84.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.13 |
| Education | $84.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,412.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,714.63 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,159.88 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $552.39 | 2022-2024 | Zeposia |
| Pfizer INC. | $357.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.76 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $279.17 | 2019-2024 | Dificid, Zerbaxa |
| Genzyme Corporation | $230.10 | 2022-2025 | |
| Amgen INC. | $210.88 | 2022-2023 | Amjevita |
| Regeneron Healthcare Solutions, INC. | $196.46 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $192.24 | 2024-2025 | Omvoh |
| Shionogi INC | $181.17 | 2019-2020 | |
| Madrigal Pharmaceuticals | $164.06 | 2025 | Rezdiffra |
| Ucb, INC. | $139.02 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $133.47 | 2023-2024 | Idacio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $121.01 | 2019-2025 | Sutab, Suflave |
| Organon LLC | $118.92 | 2023-2025 | Renflexis, Hadlima |
| Celltrion USA INC. | $118.77 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Daiichi Sankyo INC. | $109.52 | 2020-2025 | Injectafer |
| Ardelyx, INC. | $99.47 | 2023 | Ibsrela |
| Qol Medical, LLC | $92.20 | 2022-2025 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.51 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $91.05 | 2022-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $77.61 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $53.52 | 2021-2022 | |
| Sandoz INC. | $49.21 | 2023-2024 | Hyrimoz |
| Novo Nordisk INC | $48.38 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $42.86 | 2022 | |
| Capsovision, INC. | $36.39 | 2024 | Capsocam Plus |
| Mylan Institutional INC. | $35.18 | 2023 | Hulio |
| W. L. Gore & Associates, INC. | $33.81 | 2023 | Gore Cardioform Septal Occluder |
| Gilead Sciences, INC. | $23.07 | 2024 | |
| Biocon Biologics INC | $20.03 | 2024 | Hulio |
| Redhill Biopharma INC. | $15.82 | 2020 | |
| Alfasigma USA, INC. | $14.92 | 2020 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Phathom Pharmaceuticals, INC. | $7.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Papp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.